The RET/PTC3 oncogene arises from the fusion between the N-terminal encoding domain of the RFG gene and the tyrosine kinase encoding domain of RET receptor. RET/PTC3 is very frequent in papillary thyroid carcinomas, especially in children exposed to the Chernobyl accident. We have studied the functional consequences of the RFG ± RET fusion. Here we show that the N-terminal coiled-coil domain of RGF mediates oligomerization and activation of the kinase and of the transforming capability of RET/PTC3. In addition, the RFG coiled-coil domain mediates a physical association between RET/PTC3 and RGF proteins, rendering RFG a bona ®de substrate of RET/PTC3 kinase. Finally, we show that the coiled-coil domain of RGF is essential for the distribution of the RET/PTC3 protein at the membrane/particulate cell compartment level, where also most of the RFG protein is localized. We propose that fusion to the RFG coiled-coil domain provides RET kinase with a scaold that mediates oligomerization and re-localization of the RET/PTC3 protein, a process that may be crucial for the signalling of this speci®c RET/ PTC variant. Oncogene (2001) 20, 599 ± 608.
Introduction
Papillary thyroid carcinoma (PTC) is the most common form of thyroid malignancy and is characterized by rearrangements of the RET gene. RET encodes the tyrosine kinase membrane receptor for neurotrophic molecules of the glial cell line-derived neurotrophic factor (GDNF) family (Airaksinen et al., 1999) . In PTCs, gene rearrangements cause the fusion of the RET-kinase-encoding domain to heterologous genes, thus generating the chimeric oncogenes of the RET/ PTC family. These rearrangements occur at a somatic level and are determined by speci®c chromosomal inversions or translocations (Pierotti et al., 1998; Nikiforova et al., 2000) . Several RET/PTC oncogenes, diering in the RET fusion partner, have been identi®ed so far (Grieco et al., 1990; Bongarzone et al., 1993 Santoro et al., 1994; Klugbauer et al., 1998a; Klugbauer and Rabes, 1999; Nakata et al., 1999; Salassidis et al., 2000) . RET/PTC1 and RET/ PTC3 are the most prevalent variants (Pierotti et al., 1998) . RET/PTC rearrangements are speci®c for thyroid carcinomas of the papillary histotype and are considered early events in the tumorigenesis process because they are frequently found in clinically silent small PTCs (Viglietto et al., 1995; Sugg et al., 1998) . Finally, consistent with their role in human tumors, RET/PTC1 and RET/PTC3 oncogenes induce thyroid carcinomas in transgenic mice (Jhiang et al., 1996; Santoro et al., 1996; Powell et al., 1998) .
The RET/PTC1 (H4-RET) (Tong et al., 1997) and RET/PTC2 (RIalpha-RET) (Bongarzone et al., 1993) proteins are dimerized through the coiled-coil domains of the fusion partners and are constitutively autophosphorylated on tyrosine residues. Phosphorylation of these tyrosines, which serve as docking sites for signal transducers, is predicted to result in constant upregulation of the eects of RET signalling in cells expressing the oncoproteins. It is well-established that most of the proteins involved in receptor tyrosine kinase signalling are distributed at plasma membrane level. However, RET/PTC proteins lack the RET transmembrane domain and hence should be prevalently cytosolic. This can result in a selective defect of RET/PTC proteins to activate membrane-based signal transduction pathways. Thus, an important point to address is how (if at all) RET/PTC proteins are relocalized at plasma membrane level. Protein ± protein interactions may in¯uence RET/PTC proteins localization. It has been shown that the interaction of RET/ PTC2 with Enigma facilitates translocation of cytosolic RET/PTC2 to the plasma membrane (Durick et al., 1998) . Enigma is a 45 kD adaptor protein composed of an N-terminal PDZ domain that localizes it to the cell periphery, and by three LIM domains. Enigma associates with Y1062 of RET, or with the corresponding tyrosines of RET/PTC fusion proteins, through its second LIM domain. This association is constitutive and does not depend on Y1062 phosphorylation (Durick et al., 1996) .
The RET/PTC3 oncogene is generated by fusion of RET to the RFG gene (also named`ELE1' or`ARA70') Santoro et al., 1994) . RET/ PTC3 is frequent in sporadic papillary thyroid carcinomas and is typically found in solid PTCs, which are aggressive variants often observed in ionizing radiations-associated childhood PTCs (Nikiforov et al., 1997; Thomas et al., 1999) . The mechanisms by which the fusion of RET with RFG generates a transforming oncogene are largely unknown. The RFG gene encodes a 614-amino acid-long protein.
There are indications that RFG acts as a regulator of multiple steroid receptors. RFG interacts with the androgen receptor (`ARA70' stands for androgen receptor activator #70) (Yeh and Chang, 1996) and with peroxisome proliferator-activated receptors a (Treuter et al., 1998) and g (Heinlein et al., 1999) .
Here we report that the N-terminal coiled-coil domain of RFG is a functional oligomerization motif which may play a dual role in RET/PTC3-mediated cell transformation. This domain mediates the oligomerization of RET/PTC3 molecules and their kinase activation. It mediates also the interaction between RFG, which is mainly localized in the membrane/ particulate cell compartment, and RET/PTC3 proteins; this interaction results in RFG phosphorylation and in the re-localization of the RET/PTC3 kinase to the plasma membrane.
Results

RFG contains a functional oligomerization motif
The N-terminal region of RFG, which is fused to RET after the RET/PTC3 rearrangement, contains a potential coiled-coil domain (amino acids 31 ± 91) ( Figure 1a) . A series of experiments was performed to ascertain whether this RFG domain is a functional oligomerization motif.
The human RFG coding sequence was fused in-frame to the myc epitope to obtain a tagged RFGmyc construct. 293T cells were transfected with the RFGmyc plasmid and protein extracts from transfected (Figure 1b, bottom) . To assess whether RFG forms oligomers, the association between the exogenous RFGmyc and the endogenous RFG protein was evaluated by co-immunoprecipitation. Protein extracts of transfected cells were immunoprecipitated with anti-myc and blotted with anti-RFG antibodies. As shown in Figure 1b , the endogenous 60 kDa RFG protein associated with the transfected 62 kDa RFGmyc protein.
We next subcloned a cDNA fragment encoding the N-terminal 238 residues of RFG into the pCEFL-Ha vector fused to the in¯uenza virus Ha epitope ( Figure  1a ). The Ha-RFG(N) plasmid was co-expressed with RFGmyc in 293T cells. Protein lysates were immunoprecipitated with anti-Ha and the immunoblot was revealed with anti-myc antibodies. RFGmyc and Ha-RFG(N) formed stable complexes ( Figure 1c , lane 2); the signal was not detected in either untransfected cells (7) or cells transfected with RFGmyc alone ( Figure  1c, lane 1) . Thus, the oligomerization of RFG is mediated by its N-terminal portion. Immunoblots with anti-myc or anti-HA antibodies were performed to show constructs' expression.
We used the yeast two-hybrid assay to verify the capability of the N-terminal portion of RFG to form oligomers in living cells. The hybrid bait consisted of the 238 N-terminal residues of RFG fused to the GAL4 DNA-binding domain RFG(N)-GAL4(DBD). It was simultaneously transformed in yeast cells with a vector encoding the whole RFG protein fused to the GAL4 activation domain, RFG-GAL4(AD). Under these conditions, the growth of yeast cells in medium lacking adenosine and histidine depends on the reconstitution of a functional GAL4 transcription factor. Transformants were plated on selective medium (Ade 7 and His
7
) and their growth was monitored after 48 h of incubation. Yeast cells grew in selective media only when simultaneously transformed with RFG(N)-GAL4(DBD) and RFG-GAL4(AD), indicating an interaction between the two proteins. They did not grow when transfected with each plasmid alone or in combination with the corresponding empty vector (Figure 1d ).
Finally, we produced a recombinant RFG protein, and measured, by fast protein liquid chromatography (FPLC), its ability to form aggregates in solution. To this aim, the N-terminal 238 residues of RFG were expressed in Escherichia coli as a recombinant protein fused to the glutathione-S-transferase (GST) moiety. The GST-RFG(N) protein was puri®ed on glutathione beads and cleaved with thrombin to remove the GST portion (Figure 2b ). The molecular mass of the soluble RFG(N) was calculated by gel ®ltration chromatography. A calibration curve was obtained with molecular weight standards ranging from 13 700 (ribonuclease A) to 669 000 (thyroglobulin). Consistent with its predicted molecular weight, the relative molecular mass of RFG(N) was 24 kDa. However, in addition to the 24 kDa monomeric species, the chromatographic pattern revealed three major species of 48, 72 and 96 kDa, most likely corresponding to dimeric, trimeric and tetrameric derivatives, respectively. Approximately 60% of RFG(N) was in the tetrameric form ( Figure  2a ).
Taken together these results demonstrate that the Nterminal portion of RFG contains a functional oligomerization motif able to mediate the formation of dimers and of higher molecular weight oligomers.
An intact coiled-coil domain is essential for the transforming activity of RET/PTC3
Since the RFG oligomerization motif is retained in all RFG ± RET chimeric oncogenes (RET/PTC3r1, r2 and r3) described so far (Klugbauer et al., 1998b) (Figure  3a ), it could mediate RET/PTC3 kinase activation. To test this possibility, two partially deleted mutants, RET/PTC3del1 and RET/PTC3del2, were generated. RET/PTC3del1 lacked a portion of the RFG coiledcoil motif (the last three heptads), while this domain was intact in RET/PTC3del2, which lacked only the RFG sequence between the coiled-coil and the breakpoint most frequently isolated (r1) (Figure 3a) . The oligomerization potential of the various RET/PTC3 constructs was investigated by assessing their association with Ha-RFG(N) by co-immunoprecipitation. We then asked whether oligomerization was essential for RET/PTC3 activation. Dimerization-mediated activation of protein tyrosine kinases results in autophosphorylation of the protein on tyrosine residues. Thus, we measured the tyrosine phosphorylation levels of the RET/PTC3, RET/PTC3del1 and RET/PTC3del2 proteins by immunoprecipitating equal amounts of the three proteins with anti-RET antibodies and blotting with anti-phosphotyrosine antibodies. While the RET/ PTC3 and RET/PTC3del2 proteins had high levels of constitutive phosphorylation, phosphorylation of RET/ PTC3del1 was barely detectable (Figure 3c ). Finally, to determine whether oligomerization was essential for the oncogenic activity of RET/PTC3, the transforming ability of the various constructs was assessed by a focus formation assay of NIH3T3 ®broblasts. A representative example of one assay is shown in Figure  4b and the average results of three experiments are reported in the bar-graphs of Figure 4a . The RET/ PTC3del1 mutant was at least 10-fold less potently transforming than wild type RET/PTC3 and RET/ PTC3del2. These experiments demonstrate that the Nterminal portion of RFG-coiled-coil domain is essential for RET/PTC3 activation.
The RFG protein interacts with RET/PTC3 kinase RET/PTC rearrangements occur in the heterozygous state. Thus, in neoplastic cells harbouring the rearrangement, intact RFG protein encoded by the unrearranged allele co-exists with RET/PTC3. Because the RFG coiled-coil domain is present in both RFG and RET/PTC3, it could serve as a means for the two proteins to interact in living cells. To test this possibility, RET/PTC3 was co-expressed with RFGmyc in 293T cells; protein lysates were immunoprecipitated with anti-RFG and blotted with anti-RET antibodies. RET/PTC3 co-precipitated with RFGmyc indicating that the two proteins associate in vivo (Figure 5a , lane 4); as a negative control we used cells transfected with RFGmyc alone (Figure 5a, lane 3) . Anti-RET immunoprecipitates were used to con®rm RET/PTC3 protein expression (Figure 5a, lanes 1 and 2) .
Because of their physical association, RFG could have been phosphorylated by RET/PTC3 kinase. To address this point, RFGmyc was transiently expressed alone or with RET/PTC3 or its dimerization-defective mutant (RET/PTC3del1); cells were harvested and protein extracts were immunoprecipitated with antimyc and the blot was stained with anti-phosphotyrosine antibodies. Figure 5b (lane 4) shows that RET/ PTC3 stoichiometrically co-precipitated with RFGmyc and that both proteins were phosphorylated on tyrosine residues. This was speci®c because RET/ PTC3del1 neither associated to RFG nor caused RFG phosphorylation (Figure 5b, lane 2) . To assess whether RET/PTC3 kinase was responsible for RFG phosphorylation, a kinase-de®cient point mutant of RET/PTC3 was generated in which the catalytic lysine was replaced with a methionine. Co-expression of RFG with the kinase-dead RET/PTC3(K-) protein did not result in RFG phosphorylation (Figure 5b, lane 3) . Immunoblots with anti-RET or anti-myc antibodies were performed to demonstrate the expression of the various proteins (Figure 5b) .
Finally, we evaluated the co-immunoprecipitation between endogenous RFG protein and stably transfected RET/PTC3 in PC Cl 3 thyroid epithelial cells. The results reported in Figure 5c indicate that RET/ In conclusion, the RFG coiled-coil domain mediates a RFG ± RET/PTC3 heterodimerization that results in phosphorylation of RFG in cells expressing RET/ PTC3.
The RFG protein promotes re-localization of RET/PTC3 kinase To de®ne the subcellular distribution of RFG, lysates of RFGmyc-transfected 293T cells and of untransfected PC Cl 3 thyroid cells were fractionated in cytosolic and membrane/particulate (which contains plasma membrane, mitochondria, Golgi, lysosomes and vesicles) fractions. The subcellular fractions were immunoblotted with anti-myc or anti-RFG antibodies to detect transfected and endogenous RFG protein, respectively. Both transfected RFGmyc (Figure 6a ) and endogenous RFG proteins ( Figure 6b ) were mainly distributed in the membrane/particulate fraction. In particular, indirect immuno¯uorescence (Figure 6c) showed that at least a fraction of RFG was distributed in the cell periphery, suggestive of a plasma membrane localization. Low levels of the RFG protein were inconstantly found in the nuclear fraction (data not shown).
Then, we investigated the subcellular localization of RET/PTC3. To this aim, 293T cells were transfected with RET/PTC3, or its coiled-coil (del1) or kinasede®cient (K7) mutants. Transfected cells were fractionated and the subcellular fractions were immunoblotted (Figure 7a ). The localization in the membrane/particulate cell compartment depended on the integrity of the coiled-coil domain of RET/PTC3 since it was virtually abrogated in the case of the del1 mutant (Figure 7b ). It was possible that the coiled-coil domain in¯uenced indirectly the localization of the RET/PTC3 protein by promoting its kinase activity. In turn, RET/PTC3 autophosphorylation may determine a phosphotyrosine-dependent docking to membrane proteins. However, this possibility was excluded because the kinasedead RET/PTC3 mutant maintained the partial localization in the membrane/particulate cell compartment (Figure 7c) .
Based on our ®nding that RFG is mostly distributed at membrane level and is constitutively associated with RET/PTC3, we hypothesized that the membraneanchored RFG protein may target RET/PTC3 to the membrane compartment. According to this hypothesis, RFG over-expression should promote membrane localization of RET/PTC3. Thus, 293T cells were transfected with RET/PTC3 or its coiled-coil defective mutant, RET/PTC3del1, alone or with RFGmyc. The cells were homogenized and fractionated into the cytosolic and membrane fractions. The subcellular fractions were resolved by SDS ± PAGE, followed by Western blotting with anti-RET or anti-myc antibodies to analyse the relative distribution of RET/PTC3 and RFGmyc proteins. As shown in Figure 7d , when expressed alone, RET/PTC3 was localized to both the soluble and particulate compartments; instead, when coexpressed with RFGmyc, most of the RET/PTC3 was localized to the particulate fraction. The RET/ PTC3del1 mutant remained localized to the soluble fraction also when co-expressed with RFG (Figure 7e ).
Shc is a major interactor of wild type and rearranged RET versions and it is implicated in RET-mediated activation of the Ras/MAPK and P13K/Akt pathways (Hayashi et al., 2000) . However, since truncated RET/PTC oncoproteins lack the membrane-localization signals, their interaction with Shc is expected not to promote Shc recruitment to the plasma membrane. Thus, we have investigated whether RFG promoted RET/PTC3-mediated recruitment of the Shc adaptor to the membrane/particulate cell fraction. We measured by immunoblot the re-localization of Shc proteins to the membrane-particulate cell fraction in 293T cells expressing RET/PTC3 alone or in combination with RFG. A small amount of Shc was found in the membrane fraction upon expression of RET/PTC3 alone; however, when RET/PTC3 was overexpressed together with RFG a signi®cantly increased fraction of Shc was re-distributed in the membrane compartment (Figure 7d ). 
Discussion
Fusion of receptor tyrosine kinases to heterologous genes is a common activation mechanism of receptor tyrosine kinases in neoplasia. Rearrangement-promoted dimerization of the truncated kinase is essential for its activation (Rodrigues and Park, 1994) . In turn, constitutive phosphorylation of the active kinase generates docking sites for signalling proteins, resulting in constant up-regulation of signalling eects in cells expressing the oncoprotein (Rodrigues and Park, 1994) .
We have studied the mechanisms by which fusion to RFG causes RET activation. Here, we show that the N-terminal portion of RFG contains a functional oligomerization motif that mediates oligomerization of RET/PTC3 molecules and activation of RET/PTC3 kinase. In addition, we demonstrate that fusion to the RFG coiled-coil domain provides the active RET kinase with a docking site for the wild type RFG. Protein substrates of receptor tyrosine kinases are in general characterized by docking sites, i.e., phosphotyrosine binding (PTB) or Src-homology 2 (SH2) domains. By recognising receptor phosphotyrosines, these docking sites provide a means whereby enzyme and substrate can physically interact, thus resulting in the phosphotransfer reaction (Pawson and Scott, 1997) . We show that fusion to the coiled coil domain of RFG provides RET kinase with a novel docking site which recruits RFG and mediates its phosphorylation. Based on the evidence that the N-terminal domain of RFG forms trimers and tetramers in solution, the RFG-RET/PTC3 complex is not expected to negatively aect RET/PTC3 homodimerization. It is tempting to speculate that phosphorylation alters RFG function in tumors harbouring the RET/PTC3 rearrangement. Validation of this hypothesis awaits a more detailed understanding of the normal function of RFG. Recent evidence indicates that RFG is a co-activator of multiple steroid receptors as the androgen receptor (Yeh and Chang, 1996) and the peroxisome proliferator-activated receptors a (Treuter et al., 1998) and g (Heinlein et al., 1999) . Such RFG function could be altered by RET/PTC3 expression.
Biochemical fractionation showed that most RFG protein is distributed at the membrane/particulate cell compartment; speci®cally, indirect immuno¯uorescence suggested that at least a portion of the RFG protein is located at cell periphery. We have also observed that a fraction of RET/PTC3 is distributed in the particulate/ membrane compartment. This distribution is lost in the case of the coiled-coil RET/PTC3 mutant (RET/ PTC3del1). Since RET/PTC3 is constitutively associated with RFG and RFG over-expression further promotes the membrane distribution of RET/PTC3, we believe that the intact RFG protein can tether the cytosolic RET/PTC3 oncoprotein to the plasma membrane in cells expressing both RFG and RET/ PTC3. The possibility that the coiled-coil domain of RFG targets RET/PTC3 to the plasma membrane directly and not by mediating its docking to the intact RFG protein cannot be excluded. However, this possibility seems less likely because a RFG mutant deprived of the coiled-coil domain retains membrane compartimentalization, suggesting that the RFG`membrane localization domain' is mapped in the C-terminal and not in the N-terminal half of the protein (Monaco C, Barone MV and Santoro M, unpublished observations). Structurally, RFG does not contain canonical membrane-targeting domains and its localization may be mediated by protein-or lipid-mediated interactions.
In any event, membrane-docking is probably relevant for RET/PTC3 signalling. Once deprived of the transmembrane domain by the rearrangement, the truncated RET kinase is expected to be distributed in the cytosolic compartment. However, recent studies have demonstrated that mitogenic signals induced by another RET/PTC protein, RET/PTC2 (the fusion between the RIalpha subunit of protein kinase A and RET kinase), require localization of RET/PTC2 to the plasma membrane (Durick et al., 1998) . In agreement with these ®ndings, the membrane-localized protein Enigma recruits RET/PTC2 by binding to its tyrosine 586, which corresponds to tyrosine 1062 in the C-tail of the wild type RET receptor. Once translocated to the plasma membrane, RET/PTC2 recruits Shc and mediates Ras activation (Durick et al., 1998) .
Based on our ®ndings on the binding of RFG to RET/PTC3 protein, we propose an alternative model for the membrane translocation of this speci®c RET/ PTC oncoprotein and for Shc recruitment to the membrane. The Enigma-and RFG-mediated translocations of RET/PTC proteins to the membrane appear to be independent mechanisms. Docking to Enigma requires a speci®c tyrosine residue of the RET oncoprotein (the tyrosine corresponding to Y1062 in wild type RET), while RFG-mediated translocation requires an intact coiled-coil domain of the oncoprotein. The two events, by involving dierent domains of the RET/PTC3 protein, may be cooperative rather than exclusive. Furthermore, Enigma-mediated translocation should work in the case of all RET/PTC variants, because all maintain the Enigma-binding site, while RFG-mediated translocation appears to be speci®c for RET/PTC3. The fusion to heterologous gene partners may be a general mechanism for altering the subcellular distribution of the active kinase. In this regard it is intriguing to observe that the RIalpha regulatory subunit of protein kinase A, the RET fusion partner in the RET/PTC2 rearrangement, is also compartmentalized in cells through tethering to the D-AKAP1 and D-AKAP2 anchoring proteins (Huang et al., 1997a,b) .
Dierent RET/PTC variants are associated with dierent subtypes of papillary cancer. It is possible that the novel protein ± protein interactions mediated by the speci®c dimerizating motifs of the fusion partners and the dierent localization of activated RET/PTC kinases aect the signalling of the speci®c RET/PTC isoforms. Should this be the case, we now have a framework within which to examine the correlations between a speci®c RET/PTC rearrangement and the associated tumoral phenotype.
Materials and methods
Expression plasmids
To obtain RFGmyc, the human RFG coding sequence was fused to the myc epitope (EQKLISEEDLN) in the pcDNA3.1(7)Myc-His vector (Invitrogen, San Diego, CA, USA). The Ha-RFG(N) construct was generated by cloning the N-terminal coding sequence of RFG (amino acids 2 ± 238) downstream the hemagglutinin (Ha) epitope (YPYDVPDYA) in the pCEFL-Ha vector. The pBABE-RET/PTC3 construct was generated by cloning the RET/PTC3 coding sequence in the EcoRI ± SalI sites of the pBABE vector. To obtain RET/ PTC3(K7), a kinase-dead RET/PTC3 mutant lacking the catalytic ATP-binding site, the lysine residue of RET/PTC3 corresponding to lysine 758 of wild type RET was replaced with a methionine by recombinant PCR. The RET/PTC3del1 and RET/PTC3del2 constructs were generated by deleting dierent portions of RFG from pBABE-RET/PTC3: the RFG portion fused to the tyrosine kinase domain of RET consisted of residues 1 ± 65 (RET/PTC3del1) or 1 ± 108 (RET/ PTC3del2). The constructs were sequenced by the Sequenase Kit (USB, Cleveland, OH, USA).
Antibodies
A polyclonal anti-RFG antibody was generated by immunizing rabbits with a GST-RFG fusion protein containing the C-terminal 376 residues of the human protein. They were anity-puri®ed by sequential chromatography steps through GST and GST-RFG columns (AminoLink, Pierce, Rockford, IL, USA) and were used at 1 mg/ml for immunoprecipitation and at 0.1 mg/ml for Western blotting. Polyclonal anitbodies against RET recognize its tyrosinekinase domain (Santoro et al., 1996) . Anti-eps15 antibodies were provided by Dr Di Fiore (Fazioli et al., 1993) . Mouse monoclonal anti-Ha epitope antibodies (clone 12CA5) were purchased from Boehringer Mannheim (Mannheim, Germany). The 4G10 anti-pTyr monoclonal antibody was purchased from Upstate Biotechnology (Lake Placid, NY, USA). The 9E10 anti-myc epitope monoclonal antibody, mouse monoclonal anti-YY1, anti-Shc antibodies, and secondary anti-mouse or anti-rabbit antibodies coupled to horseradish peroxidase were purchased from Santa Cruz Biotechnology (CA, USA). Texas red-conjugated secondary antibodies were from Boehringer ± Mannheim (Mannheim, Germany).
Recombinant proteins
The GST-RFG(N) fusion protein was generated by cloning the N-terminal portion of the human RFG cDNA (amino acids 2 ± 238) in the pGEX2T vector (Amersham Pharmacia Biotech). The GST-RFG(N) protein was expressed in bacteria and puri®ed with glutathione-conjugated Sepharose beads (Sigma, St. Louis, MO, USA) by standard procedures. To separate the GST from the RFG component, GST-RFG(N)-bound Sepharose was digested with 10 units of thrombin over-night at room temperature. The digests were washed twice with PBS containing protease inhibitors and 1 mM EDTA and pooled, and the eluate was used for fast protein liquid chromatography (FPLC). The sample (30 mg) was analysed on a Hi-Load Superdex 200 (10/30) column (Pharmacia), equilibrated in 50 mM sodium phosphate buer, pH 7.0, containing 0.15 M NaCl at a¯ow rate of 0.3 ml/min. Thyroglobulin (669 kDa), ferritin (440 kDa), IgG (160 kDa), bovine serum albumin (67 kDa), ovalbumin (45 kDa), and ribonuclease A (13.7 kDa) were used as standards for the molecular mass calibration curve.
Protein studies
Protein concentration was estimated by a modi®ed Bradford assay (Bio-Rad, Munich, Germany). Immunoblots were performed with 50 mg of total lysates; 500 mg of protein lysates were used for immunoprecipitations. Immunocomplexes were revealed by the enhanced chemiluminescence detection kit (ECL, Amersham, Buckinghamshire, UK). For fractionation experiments, cells were lysed in hypotonic buer (20 mM HEPES pH 7.5, 5 mM EGTA and inhibitors of proteases and phosphatases). Nuclei (N) were recovered by centrifugation at 1000 g and their homogeneity was microscopically controlled. The supernatant was centrifuged at 100 000 g for 45 min to separate the cytosolic from the membrane/particulate cell fraction.
Two-hybrid analysis
The N-terminal portion of the human RFG protein (amino acids 2 ± 238) was fused in frame to the GAL4 DNA-binding domain in the pGBKT7 vector (Clontech), carrying the TRP1 selection [(RFG(N)-GAL4(DBD)]. The full-length RFG cDNA was fused in-frame to the GAL4 activation domain in the pGADT7 vector (Clontech) carrying the LEU2 selection [RFG-GAL3(AD)]. The two plasmids were simultaneously transformed or co-transformed with the corresponding empty vector in the S. cerevisiae yeast strain AH109. 
Cell culture experiments
Rat thyroid epithelial cells PC Cl 3 and PC Cl 3 expressing RET/PTC3 (Santoro et al., 1993) were cultured in Ham F12 supplemented with 5% calf serum, thyroid stimulating hormone and insulin (GIBCO ± BRL, Life Technologies, Gaithersburg, MD, USA). NIH3T3 cells were grown in Dulbecco Modi®ed Eagle's Medium (DMEM) supplemented with 10% calf serum (GIBCO ± BRL, Life Technologies, Gaithersburg, MD, USA). For the focus formation assay, NIH3T3 cells were transfected with 1 mg of the dierent constructs as described elsewhere (Grieco et al., 1990) . Transformed foci were scored at 2 weeks. Transforming eciency was calculated in focus-forming units per picomole of added DNA after normalization for the eciency of colony formation in parallel dishes subjected to marker selection. Human embryonal kidney 293T cells were grown in DMEM supplemented with 10% fetal calf serum and were transfected by the calcium phosphate precipitation technique.
Indirect immunofluorescence
293T cells transfected with RFGmyc (2 mg) were plated onto coverslips and at 72 h post-transfection they were processed for indirect immuno¯uorescence. Coverslips were washed in phosphate buer solution (PBS) containing Hoechst 33258 (®nal concentration, 1 mg/ml, Sigma), rinsed in water, and mounted in Moviol on glass slides. The¯uorescent signal was visualized with an epi¯uorescent microscope (Axiovert 2, Zeiss). In each experiment, at least 60 transfected cells were analysed.
